Billingsley PF, Richie TL, Abdulla S, Ondo'o Ayekaba M, Daubenberger CA, Garcia GA, Hoffman SL. A paradigm for Africa-centric vaccine development in Equatorial Guinea.
Trends Parasitol 2024:S1471-4922(24)00072-2. [PMID:
38582683 DOI:
10.1016/j.pt.2024.03.005]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 02/26/2024] [Accepted: 03/12/2024] [Indexed: 04/08/2024]
Abstract
The Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).
Collapse